Literature DB >> 31034039

G-CSF-mobilized peripheral blood mononuclear cells combined with platelet-rich plasma accelerate restoration of ovarian function in cyclophosphamide-induced POI rats†.

Qiuyan Huang1, Bo Liu1, Rufang Jiang1, Shengbin Liao1, Zhiyao Wei1, Yin Bi1, Xueyuan Liu2, Rong Deng1, Yufu Jin1, Ying Tan1, Yihua Yang1, Aiping Qin1.   

Abstract

Peripheral blood mononuclear cells (PBMCs) are rich in hematopoietic cells and mesenchymal stem cells. Platelet-rich plasma (PRP) is rich in various growth factors. PBMCs and PRP have been suggested, individually, to restore ovarian function by improving the local microenvironment. The current study investigated the effect of granulocyte colony-stimulating factor (G-CSF)-mobilized PBMCs combined with PRP on restoring ovarian function in rats with primary ovarian insufficiency (POI). Thirty adult female rats were randomly subdivided into five groups: normal control (control), cyclophosphamide (CTX) plus subsequent PBS (POI + PBS), CTX plus subsequent PRP (POI + PRP), CTX plus subsequent G-CSF-mobilized PBMCs (POI + PBMCs), and CTX plus subsequent G-CSF-mobilized PBMCs combined with PRP (POI + PBMCs + PRP). CTX exposure induced the typical POI phenotype with increased diestrus; shortened estrus; follicle arrest at all stages; decreased serum levels of estradiol-17β (E2) and anti-Mullerian hormone (AMH); and increased levels of follicle-stimulating hormone (FSH). Transplantation of mobilized PBMCs with PRP resulted in a much earlier restoration of the estrous cycle, sex hormone levels, and preantral follicle growth in POI rats. Expression of the male-specific Sry gene in the ovarian tissues of POI + PBMCs + PRP female recipient rats was evident at 5, 10, and 20 days posttransplantation along with significant increases in the expression of angiogenesis markers CD34+ and VEGF and folliculogenesis markers AMH and FSHR. Additionally, PBMCs in combination with PRP mitigated granulosa cell apoptosis by downregulating BAX and upregulating BCL-2. These results demonstrate that G-CSF-mobilized PBMCs combined with PRP accelerate the restoration of ovarian function in POI rats by increasing ovarian neovascularization, reducing granulosa cell apoptosis, and promoting folliculogenesis.
© The Author(s) 2019. Published by Oxford University Press on behalf of Society for the Study of Reproduction.

Entities:  

Keywords:  peripheral blood mononuclear cells; platelet-rich plasma; primary ovarian insufficiency; rats

Year:  2019        PMID: 31034039     DOI: 10.1093/biolre/ioz077

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  5 in total

1.  The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage.

Authors:  Pinar Ozcan; Taha Takmaz; Olgu Enis Tok; Sevde Islek; Esra Nur Yigit; Cem Ficicioglu
Journal:  J Assist Reprod Genet       Date:  2020-02-04       Impact factor: 3.412

Review 2.  Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action.

Authors:  Serin Seckin; Hadi Ramadan; Marco Mouanness; Michelle Kohansieh; Zaher Merhi
Journal:  J Assist Reprod Genet       Date:  2022-02-17       Impact factor: 3.412

Review 3.  Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review.

Authors:  Jeeyoon Na; Gi Jin Kim
Journal:  J Ovarian Res       Date:  2020-06-23       Impact factor: 4.234

4.  Assessment role of total phenols and flavonoids extracted from Pleurotus columbinus mushroom on the premature ovarian failure induced by chemotherapy in rats.

Authors:  Amal I Hassan; Mona A M Ghoneim; Manal G Mahmoud; Mohsen S Asker
Journal:  J Genet Eng Biotechnol       Date:  2021-12-10

5.  Protective effect of alpha-lipoic acid and omega-3 fatty acids against cyclophosphamide-induced ovarian toxicity in rats.

Authors:  Dhanya Venugopalan Nair; M Usha Rani; A Gopala Reddy; B Kala Kumar; M Anudeep Reddy; M Lakshman; U Rajkumar
Journal:  Vet World       Date:  2020-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.